Lack of Clinical Proof-of-Concept Data
Pipelines Focused Mainly on Preclinical Stages
"Department Store-Style" R&D and Closed Governance Structure

Editor's NoteThe global pharmaceutical and biotech industry is experiencing an unprecedented boom period for mergers and acquisitions (M&A). As of August this year, more than 276 trillion won in investment has flowed into the global bio M&A market, yet there have been no "big deals" involving domestic companies. This is a bitter pill to swallow for Korean biotech, which is increasingly being recognized for its industrial competitiveness in the global market. In terms of drug development pipelines, Korea ranks third in the world after the United States and China, and many innovative drug companies are receiving repeated attention at overseas conferences and exhibitions. However, it is clear that there are limits to the funding and investment exit market, which relies solely on initial public offerings (IPOs). This series examines why our bio technology companies are being sidelined and seeks solutions for fundamental competitive improvement as well as strategies for overcoming barriers in the funding market.

['Cold Shoulder for K-Bio in M&A] ①: Despite 276 Trillion Won in the First Half, Korea, the World’s No. 3, Is Left Out


['Cold Shoulder for K-Bio in M&A] ②: Korea Trapped by Data, Clinical, and Governance Pitfalls


['Cold Shoulder for K-Bio in M&A] ③: "Streamline Pipelines and Focus on Core Capabilities and Unique Technologies"


Industry experts point to the lack of key data demanded by global acquirers, the "department store" approach to development pipelines, and closed governance structures as major reasons why Korean pharmaceutical and biotech companies struggle to gain visibility in the global M&A market.


At a more fundamental level, the lack of clinical proof-of-concept (PoC) data demonstrating the commercial viability and efficacy of new drug pipelines is highlighted as a core problem. Clinical proof-of-concept refers to the process in which it is first confirmed whether a potential new drug actually demonstrates the intended therapeutic effect (efficacy) and safety in real patients.


Lee Seung-kyou, Vice Chairman of the Korea Biotechnology Industry Organization(KoreaBIO), is being interviewed by The Asia Business Daily at the KoreaBIO office in Seongnam, Gyeonggi Province. Photo by Jeong Dong-hoon

Lee Seung-kyou, Vice Chairman of the Korea Biotechnology Industry Organization(KoreaBIO), is being interviewed by The Asia Business Daily at the KoreaBIO office in Seongnam, Gyeonggi Province. Photo by Jeong Dong-hoon

View original image

Lee Seung-kyou, Vice Chairman of the Korea Biotechnology Industry Organization(KoreaBIO), stated on the 3rd, "U.S. and Chinese companies generally enter deal negotiations with major pharmaceutical firms after securing solid phase 2a or 2b clinical data, but Korean companies are largely limited to presenting only non-clinical or preclinical data." He explained that, in addition, structural differences in factors such as regulatory approval processes and the speed of patient enrollment in Korea have hindered the closing of qualitative gaps, making it challenging for domestic firms to achieve real data competitiveness.


This reality is backed by statistics. According to the National New Drug Development Project (KDDF)'s survey of domestic new drug pipelines, the earliest stage—discovery—accounts for 851 out of all pipelines, representing 39.4%, the highest share. The non-clinical and preclinical stages, targeting cells or animals to verify efficacy and safety before human trials, numbered 760, or 35.2%.


Pipelines at stages prior to entering full-scale human clinical trials accounted for 1,611 out of a total 2,162 pipelines, or 74.6%. In contrast, only 25.4% had advanced to or beyond the clinical trial threshold, while just five pipelines—0.2% of the total—had reached the final commercial stages of New Drug Application (NDA) or Biologics License Application (BLA).

['K-Bio Falling Behind in M&A] ② Korea Caught in the Traps of Data, Clinical Results, and Corporate Governance View original image

Lack of selectivity and concentration in pipeline development is another reason Korean firms are being overlooked by global acquirers. Hwang Man-soon, CEO of Korea Investment Partners, explained, "For M&A, you need a focused core pipeline with a unified direction, but domestic companies tend to have asset portfolios structured like department stores, scattered without focus." He further noted, "An R&D strategy that expands pipeline numbers based on trends, without allocating adequate resources and personnel to secure core data such as biomarkers or patent strategies that can highlight the probability of success, does not help realize global deals at all."


Founders' desire to retain management control and a tendency for unilateral decision-making also act as obstacles. While, in the U.S. ecosystem, the acquisition of a promising venture by a global pharmaceutical giant marks the completion of a successful startup, there remains a strong belief domestically that founders must see drug development through on their own to the end.



With global pharmaceutical firms increasingly seeking 100% equity acquisitions to gain full control over candidate compounds, this divergence from domestic founders' perspectives has led to missed opportunities to objectively evaluate company growth and to time equity sales appropriately.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing